Beijing-based pharma, BeiGene’s Brukinsa (zanubrutinib) has been approved by the US Food and Drug Administration (FDA) for chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma (SLL).

AstraZeneca has secured a key approval for its BTK inhibitor Calquence in Europe, which the company has said could be a blockbuster new indication for the drug. The European Commission has cleared ...